Zobrazeno 1 - 10
of 218
pro vyhledávání: '"N Woolacott"'
Autor:
G Norman, R Faria, F Paton, A Llewellyn, D Fox, S Palmer, I Clifton, J Paton, N Woolacott, C McKenna
Publikováno v:
Health Technology Assessment, Vol 17, Iss 52 (2013)
Background: Allergic asthma is a long-term disorder of the airways resulting from overexpression of immunoglobulin E (IgE) in response to environmental allergens. Patients with poorly controlled asthma are at high risk of exacerbations requiring addi
Externí odkaz:
https://doaj.org/article/2b59d2ca8266412b8e2c41ea034ea69b
Publikováno v:
Health Technology Assessment, Vol 16, Iss 34 (2012)
Background: For patients who continue to have seizures despite ongoing treatment, surgical resection of the epileptic focus may be considered, and can result in seizure-freedom. Currently, non-invasive tests provide information to inform the scope an
Externí odkaz:
https://doaj.org/article/eb18441755db400f91d5b6a53c389745
Publikováno v:
Health Technology Assessment, Vol 16, Iss 14 (2012)
Background: EOS is a biplane X-ray imaging system manufactured by EOS Imaging (formerly Biospace Med, Paris, France). It uses slot-scanning technology to produce a high-quality image with less irradiation than standard imaging techniques. Objective:
Externí odkaz:
https://doaj.org/article/ee2decdae9b94e9d9f8ae1d9a8e92bac
Publikováno v:
Health Technology Assessment, Vol 15, Iss Suppl 1 (2011)
Externí odkaz:
https://doaj.org/article/8a87133690c5460393191895493d9044
Publikováno v:
Health Technology Assessment, Vol 15, Iss Suppl 1 (2011)
Externí odkaz:
https://doaj.org/article/e0f4a0add1ec4660b0a63825082d260b
Autor:
M Rodgers, D Epstein, L Bojke, H Yang, D Craig, T Fonseca, L Myers, I Bruce, R Chalmers, S Bujkiewicz, M Lai, N Cooper, K Abrams, D Spiegelhalter, A Sutton, M Sculpher, N Woolacott
Publikováno v:
Health Technology Assessment, Vol 15, Iss 10 (2011)
Background: Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment. Objective: To determine the clinical effec
Externí odkaz:
https://doaj.org/article/d3f259c8dd5e4d6080a7bc5c4de89605
Publikováno v:
Health Technology Assessment, Vol 14, Iss Suppl 2 (2010)
Externí odkaz:
https://doaj.org/article/7c098943c263405daf88d49775554fe7
Autor:
D Chambers, M Paulden, F Paton, M Heirs, S Duffy, D Craig, J Hunter, J Wilson, M Sculpher, N Woolacott
Publikováno v:
Health Technology Assessment, Vol 14, Iss 39 (2010)
Background: Sugammadex (Bridion®) is a newly developed agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Sugammadex can reverse profound blockade and can be given for immediate reversal and its use would avo
Externí odkaz:
https://doaj.org/article/15bd2b3963e14ac38feedaeb231d7361
Publikováno v:
Health Technology Assessment, Vol 14, Iss Suppl 1 (2010)
Externí odkaz:
https://doaj.org/article/9b39940777904b6abd386354d6cda6be
Autor:
C McKenna, J Burch, S Suekarran, S Walker, A Bakhai, K Witte, M Harden, K Wright, N Woolacott, P Lorgelly, L Fenwick, S Palmer
Publikováno v:
Health Technology Assessment, Vol 14, Iss 24 (2010)
Background: Two aldosterone inhibitors are currently licensed for heart failure (HF) in the UK: spironolactone and eplerenone. Recent clinical guidelines recommend eplerenone after an acute myocardial infarction (MI) for patients with symptoms and/or
Externí odkaz:
https://doaj.org/article/2b79534233894c4bab1eb9ee25c1800e